Welcome - Register - Login - Help/FAQ - 0 items

Search Enter keywords, a title or a report id number below. In All Categories --------------------- Telecom & Computing Business & Finance Mfg & Construction Pharma & Healthcare Consumer & Retail Gov & Public Sector Energy & Transport Country Reports Company Reports --------------------- Transcripts Advanced      Select a currency for use throughout the site Australia Dollars Canada Dollars Euro Japan Yen Sweden Kroner Switzerland Francs UK Pounds US Dollars Search Results Your Search for 'Migraine: positioning triptans in an increasingly competitive market' returned 6 results - Page 1 of 1   Sort by    Date Published ASC Date Published DESC Report Price ASC Report Price DESC Rank ASC Rank DESC   Sorted by Rank Top-Bottom Migraine - Pipeline Assessment and Market Forecasts to 2016   GlobalData, July 2010, Pages: 47 in the growth rate can be primarily attributed to the increased competition among the existing products, the patent expiries of standard triptans, the availability of prophylactic drugs, the accessibility OTC Triptans in New Zealand   Euromonitor International, May 2011, Pages: 27 OTC triptans were first available in New Zealand in 2007, after being approved by Medsafe in 2006. The category saw rapid growth of 110% in 2008, a significantly reduced 20% increase in 2009 OTC Triptans in Sweden   Euromonitor International, July 2011, Pages: 24 Competitive Positioning Summary 3 Antula Healthcare AB: Competitive Position 2010 Executive Summary Resilience To Wider Economic Forces Liberalisation Boosts Sales Growth Increasing Concentrated Environment Novel therapeutics and future R&D   Business Insights, Jan 2007, Pages: 224 agonists Delta opiates Migraine Triptans and NSAIDs Non-serotonergic treatments Calcitonin Gene Related Peptide (CGRP) Gap junction blockers Vanilloids Ion channel blockers Other novel mechanisms The CNS Market Outlook to 2010   Business Insights, Oct 2005 of the major players are set to perform disappointingly in these traditional markets due to increasing pricing pressure from generic competition and limited differentiation among new medicines. The new report Personalized Medicine - Scientific and Commercial Aspects   Jain PharmaBiotech, Feb 2012, Pages: 780 of epilepsy Pharmacogenomics of epilepsy Drug resistance in epilepsy Future prospects for management of epilepsy Personalized management of migraine Individualization of use of triptans for migraine Results:  First -   Prev -   1 -   Next -   Last

		For enquiries please call us on:   +353-1-415-1241 (GMT Office Hours)   1-800-526-8630 (US/Canada Toll Free)   1-917-300-0470 (EST Office Hours)

All rights reserved. © Copyright 2012 Research and Markets3    Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network